Tigecycline's Link to Liver Enzyme Elevations
Tigecycline, a glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia, is associated with transient elevations in liver enzymes, primarily alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These occur in 15-25% of patients in clinical trials, typically mild and reversible without discontinuation.[1][2]
How Common Are These Elevations?
In phase 3 trials involving over 5,000 patients, ALT elevations above 3x upper limit of normal (ULN) happened in 2-9% of tigecycline-treated patients versus 1-4% on comparators like vancomycin or imipenem. Severe cases (>10x ULN) were rare (<1%), resolving post-treatment. Risk rises with longer durations (>14 days) or underlying liver disease.[1][3]
What Causes Tigecycline-Induced Enzyme Changes?
The mechanism involves direct hepatocyte toxicity from tigecycline's mitochondrial inhibition, impairing beta-oxidation and causing transient cholestasis or steatosis. Unlike true hepatotoxicity, it rarely leads to jaundice, bilirubin spikes, or liver failure—distinguishing it from idiosyncratic drug reactions.[2][4] No dose-response link exists beyond standard 100mg loading/50mg BID dosing.
Who Gets Affected Most?
Higher rates appear in patients with hepatitis C (up to 40% ALT rise), obesity, or concurrent hepatotoxins like acetaminophen. Trials excluded severe liver impairment (Child-Pugh C), but post-marketing data show safe use with monitoring in milder cases.[1][5] No pediatric-specific spike, though data is limited.
Does It Lead to Serious Liver Damage?
Progression to acute liver injury or failure is uncommon (<0.5%), with most resolving within 1-4 weeks off-drug. FDA label warns of "abnormal liver chemistries" but not hepatotoxicity black box. Hy's law cases (elevated ALT + bilirubin) occurred in <0.1%.[3][6]
Monitoring and Management
Check baseline LFTs; monitor weekly during therapy, especially >7 days. Hold or discontinue if ALT >5x ULN with symptoms or >10x ULN. No antidote; supportive care suffices.[2][7] Guidelines (IDSA) recommend tigecycline avoidance in acute hepatic failure.
How Does Tigecycline Compare to Other Antibiotics?
| Antibiotic | ALT Elevation Rate (>3x ULN) | Notes |
|------------|------------------------------|-------|
| Tigecycline | 2-9% | Transient, dose-related |
| Vancomycin | 1-3% | Less frequent |
| Levofloxacin | 1-4% | Similar profile |
| Piperacillin-tazobactam | 3-7% | Higher in combo therapy |
| Linezolid | <1% | Minimal hepatic risk[1][3] |
Switch to alternatives like eravacycline (newer glycylcycline with lower liver signal) if history of issues.[4]
Regulatory Warnings and Post-Marketing Data
FDA approved 2005 with liver enzyme warning in label; no updates post-2010 despite ~10,000 global cases. EudraVigilance reports 200+ hepatic events (mostly mild). No recalls or restrictions.[5][6]
Sources
[1] Tigecycline Prescribing Information (FDA)
[2] LiverTox: Tigecycline (NIH)
[3] Post et al., Clin Infect Dis 2005
[4] Meissner et al., Drugs 2019
[5] EMA Tigecycline Summary
[6] FAERS Database Query (FDA)
[7] IDSA Guidelines 2021